ORUM (KQ:475830) — Market Cap & Net Worth

$596.52K USD  · ₩880.24 Million KRW  · Rank #30486

Market Cap & Net Worth: ORUM (475830)

ORUM (KQ:475830) has a market capitalization of $596.52K (₩880.24 Million) as of May 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #30486 globally and #2044 in its home market, demonstrating a 8.49% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORUM's stock price ₩88200.00 by its total outstanding shares 9980 (9.98K). Analyse how efficiently does ORUM generate cash to see how efficiently the company converts income to cash.

ORUM Market Cap History: 2025 to 2026

ORUM's market capitalization history from 2025 to 2026. Data shows growth from $811.60K to $596.52K (0.00% CAGR).

ORUM Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how ORUM's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of 475830 by Market Capitalization

Companies near ORUM in the global market cap rankings as of May 4, 2026.

Key companies related to ORUM by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
  • UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
  • argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#223 Vertex Pharmaceuticals Inc NASDAQ:VRTX $107.56 Billion $423.92
#367 Regeneron Pharmaceuticals Inc NASDAQ:REGN $72.88 Billion $701.42
#517 UCB SA BR:UCB $51.45 Billion €231.20
#568 argenx NV ADR NASDAQ:ARGX $45.97 Billion $787.95

ORUM Historical Marketcap From 2025 to 2026

Between 2025 and today, ORUM's market cap moved from $811.60K to $ 596.52K, with a yearly change of 0.00%.

Year Market Cap Change (%)
2026 ₩596.52K -26.50%
2025 ₩811.60K --

End of Day Market Cap According to Different Sources

On May 4th, 2026 the market cap of ORUM was reported to be:

Source Market Cap
Yahoo Finance $596.52K USD
MoneyControl $596.52K USD
MarketWatch $596.52K USD
marketcap.company $596.52K USD
Reuters $596.52K USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About ORUM

KQ:475830 Korea Biotechnology
Market Cap
$596.52K
₩880.24 Million KRW
Market Cap Rank
#30486 Global
#2044 in Korea
Share Price
₩88200.00
Change (1 day)
-1.45%
52-Week Range
₩17010.00 - ₩143700.00
All Time High
₩143700.00
About

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more